ethyl 5-bromo-3-(3-ethoxy-3-oxopropyl)-1H-indole-2-carboxylate | 54904-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 5-bromo-3-(3-ethoxy-3-oxopropyl)-1H-indole-2-carboxylate
• 英文别名: 5-bromo-3-(2-ethoxycarbonyl-ethyl)-indole-2-carboxylic acid ethyl ester
• CAS: 54904-13-1
• 化学式: C₁₆H₁₈BrNO₄
• 分子量: 368.227
• InChiKey: AGRAPHUOTAYADI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  68.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 5-bromo-3-(3-ethoxy-3-oxopropyl)-1H-indole-2-carboxylate 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 以73%的产率得到acide (bromo-5 carboxy-2 1H-indolyl-3)-3 propanoique
  参考文献：
  名称：

  Design and synthesis of novel inhibitors of human kynurenine aminotransferase-I

  摘要：

  Herein we report 6-ethoxy-6-oxo-5-(2-phenylhydrazono) hexanoic acid and 3-(2-carboxyethyl)-1H-indole- 2-carboxylic acid derivatives as synthetically accessible leads for human kynurenine aminotransferase-I (KAT-I) inhibitors. In total, 12 compounds were synthesized and their biological activities were determined using the HPLC-UV based KAT-I inhibition assay. Of the 12 compounds synthesized, 10 were found to inhibit human KAT-I and the most active compound was found to be 5-(2-(4-chlorophenyl) hydrazono)-6-ethoxy-6-oxohexanoic acid (9a) with an IC50 of 19.8 mu M. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.138
• 作为产物：
  描述：

  2-氧代环戊羧酸乙酯 在 盐酸 、 硫酸 作用下， 以 乙醇 、 水 为溶剂， 反应 25.33h， 生成 ethyl 5-bromo-3-(3-ethoxy-3-oxopropyl)-1H-indole-2-carboxylate
  参考文献：
  名称：

  Design and synthesis of novel inhibitors of human kynurenine aminotransferase-I

  摘要：

  Herein we report 6-ethoxy-6-oxo-5-(2-phenylhydrazono) hexanoic acid and 3-(2-carboxyethyl)-1H-indole- 2-carboxylic acid derivatives as synthetically accessible leads for human kynurenine aminotransferase-I (KAT-I) inhibitors. In total, 12 compounds were synthesized and their biological activities were determined using the HPLC-UV based KAT-I inhibition assay. Of the 12 compounds synthesized, 10 were found to inhibit human KAT-I and the most active compound was found to be 5-(2-(4-chlorophenyl) hydrazono)-6-ethoxy-6-oxohexanoic acid (9a) with an IC50 of 19.8 mu M. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.138

文献信息

• 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS
  申请人：Song Xiaohong

  公开号：US20090124616A1

  公开（公告）日：2009-05-14

  Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.

  本发明揭示了抑制抗凋亡蛋白Mcl-1活性的化合物、含有该化合物的组合物以及治疗涉及过度表达或调节Mcl-1蛋白的疾病的方法。
• 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives
  申请人：Abbott Laboratories

  公开号：US07981888B2

  公开（公告）日：2011-07-19

  Compounds of Formula I wherein A1, B1, C1, D1, E1, F1 and L1 are as defined herein, which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein, such as leukemia and lymphoma, are disclosed.

  本文披露了化学式I的化合物，其中A1、B1、C1、D1、E1、F1和L1的定义如本文所述，这些化合物抑制抗凋亡Mcl-1蛋白的活性，包含这些化合物的组合物，以及治疗涉及过度表达或未调节的Mcl-1蛋白的疾病的方法，如白血病和淋巴瘤。
• 1-oxyalkyl-2-carboxy-7-nonsubstituted indole derivatives
  申请人：Song Xiaohong

  公开号：US08853209B2

  公开（公告）日：2014-10-07

  Compounds of Formula I wherein A1, B1, C1, D1, E1, F1 and L1 are as defined herein, which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mdl-1 protein, such as leukemia and lymphoma, are disclosed.

  本文披露了式I化合物，其中A1、B1、C1、D1、E1、F1和L1的定义如本文所述，这些化合物能够抑制抗凋亡Mcl-1蛋白的活性，以及含有这些化合物的组合物和治疗涉及过度表达或未调节的Mdl-1蛋白的疾病的方法，例如白血病和淋巴瘤。
• WO2008/130970
  申请人：——

  公开号：——

  公开（公告）日：——
• 7-NONSUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS
  申请人：AbbVie Inc.

  公开号：EP2134685B1

  公开（公告）日：2015-09-02